Series Description

FDA's Division of Drug Information in the Center for Drug Evaluation and Research (CDER) sponsors a series of educational webinars targeting the needs of health care professionals and students. The webinars cover a broad range of FDA drug regulation and medication safety topics. These focused webinars support FDA's mission of promoting and protecting public health through interaction and education to strengthen current and future partnerships and relationships with clinicians and researchers.

Lecture Description
There is a whole universe of unusual products available to consumers that claim to do everything from improve your mood, lose weight, prevent illness, or cure serious diseases. Some are relatively harmless; others could cause serious injuries or even death. The goal of this presentation is to give healthcare practitioners some insights into some of the more common product types that your patients may currently be using or may resort to depending on the situation. The topics of discussion will include quick cures, chronic conditions, cough/cold/COVID, caustic topicals, and lifestyle/recreational drugs.

References

• Medication Health Fraud: https://www.fda.gov/drugs/buying-using-medicine-safely/medication-health-fraud
• Health Fraud Scams: https://www.fda.gov/consumers/health-fraud-scams
• Health Fraud Scams are Everywhere: https://www.fda.gov/media/84561/download
• 6 Tip-offs to Rip-offs: Don't Fall for Health Fraud Scams: https://www.fda.gov/consumers/consumer-updates/6-tip-offs-rip-offs-dont-fall-health-fraud-scams
• Warning Letters - Health Fraud: https://www.fda.gov/consumers/health-fraud-scams/warning-letters-health-fraud
• Health Fraud Product Database: https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database

Series Objectives

• Explain how to utilize FDA's Drug Information, medication safety resources, and regulatory guidances to improve delivery of patient care and optimize outcomes.
• Describe and inform health care providers of recent labeling, policy and regulatory changes which would impact prescribing and medication management to optimize patient care.

Learning Objectives After completion of this activity, the participant will be able to:

• Recognize various categories of commonly used, unapproved drugs sold directly to patients.
• Identify and anticipate scenarios where a patient may resort to risky products.
• Discuss where patients may encounter fraudulent unapproved products.
• Locate where to find helpful resources related to fraud on www.fda.gov.

Target Audience
This activity is intended for physicians, pharmacists, pharmacy technicians, nurses, Certified Public Health (CPH), and physician assistants.

Registration Information
Registration is complimentary; therefore refunds are not applicable. For information on how to register to attend this activity, please contact the Activity Coordinator(s) listed above.

Requirements for Receiving CE Credit

All learners claiming credit must attest to their attendance and complete all required activity evaluation(s) in the FDA CE Portal (ceportal.fda.gov) within 14 days after an activity ends. Upon completion, learners may view/print statement of credit.

Attention NABP Pharmacists and Pharmacy Technicians: The FDA CE Team will report your credit to the National Association of Boards of Pharmacy (NABP) provided you add your NABP ID and date of birth to your profile in the FDA CE Portal. The only official Statement of Credit is the one you pull from CPE Monitor®. If you do not see your credit reflected on CPE Monitor®* after 45 days of attestation, please contact FDACETeam@fda.hhs.gov.
*CPE Monitor® sets a strict 60-day limit on uploading credits.

Disclosure

Faculty

• Pace, John, JD, Regulatory Counsel, FDA - nothing to disclose

Planning Committee

• Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
• Cao, Christian, MPAS, PA-C, Cross-Discipline Safety Advisor, FDA/CDER/OSE/OPE - nothing to disclose
• De Fronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
• Kapoor, Rama, MD, Senior Physician, FDA - nothing to disclose
• Nguyen-Chu, Thanh, PharmD, Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
• Paraoan, Dianne, MPH, BSN, RN, Associate Director for Regulatory Affairs, FDA/ CDER/ OMP - nothing to disclose

CE Consultation and Accreditation Team

• Littlefield, Jr, Kenneth P., Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
• Bryant, Traci, M.A.T., Lead Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
• Wood, Sara, Accreditation Program Administrator, CECAT, FDA/CDER/OEP/DLOD - nothing to disclose